NPPB and ischemic stroke: Numerous reports have focused on biomarkers of atrial cardiopathy and their association with the risk of AF detection, the risk of incident ischemic stroke, and the recurrence of ESUS, including increased left atrial size (Benjamin et al., 1995; Jordan et al., 2019; Kamel, Okin, et al., 2019; Perlepe et al., 2020; Yaghi et al., 2015), increased p‐wave terminal force in V1 (PTFV1) (Jalini et al., 2019; Kamel et al., 2014; Li et al., 2021), elevated N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) (Berntsson et al., 2014; Folsom et al., 2013; Llombart et al., 2015) and so on.